➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Johnson and Johnson
Mallinckrodt
Harvard Business School
Medtronic

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LCB01-0371


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug LCB01-0371?

LCB01-0371 is an investigational drug.

There have been 9 clinical trials for LCB01-0371. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2020.

The most common disease conditions in clinical trials are Tuberculosis, Pulmonary, Tuberculosis, and Communicable Diseases. The leading clinical trial sponsors are LegoChem Biosciences, Inc, Radboud University, and Ludwig-Maximilians - University of Munich.

There are three US patents protecting this investigational drug and twenty international patents.

Recent Clinical Trials for LCB01-0371
TitleSponsorPhase
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)Ludwig-Maximilians - University of MunichPhase 2
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)Radboud UniversityPhase 2
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)University of California, San FranciscoPhase 2

See all LCB01-0371 clinical trials

Clinical Trial Summary for LCB01-0371

Top disease conditions for LCB01-0371
Top clinical trial sponsors for LCB01-0371

See all LCB01-0371 clinical trials

US Patents for LCB01-0371

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LCB01-0371   Try Before You Buy Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof Legochem Biosciences, Inc. (Deajeon, KR)   Try Before You Buy
LCB01-0371   Try Before You Buy Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use Trius Therapeutics, Inc. (San Diego, CA)   Try Before You Buy
LCB01-0371   Try Before You Buy Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-- (substituted methyl)oxazolidin-2-one derivatives Legochem Biosciences, Inc. (Daejeon, KR)   Try Before You Buy
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LCB01-0371

Drugname Country Document Number Estimated Expiration Related US Patent
LCB01-0371 Australia AU2009297294 2028-09-24   Try Before You Buy
LCB01-0371 Brazil BRPI0918964 2028-09-24   Try Before You Buy
LCB01-0371 Canada CA2737299 2028-09-24   Try Before You Buy
LCB01-0371 China CN102171207 2028-09-24   Try Before You Buy
LCB01-0371 European Patent Office EP2331529 2028-09-24   Try Before You Buy
LCB01-0371 Spain ES2526120 2028-09-24   Try Before You Buy
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Colorcon
McKinsey
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.